ISIS 113715 / Ionis - LARVOL DELTA

PTP1B Inhibitors for Type 2 Diabetes: From Natural Products, Synthetic Inhibitors, and Multi-Target Drug Design Strategies to Clinical Translation. (PubMed, Curr Drug Targets) - "The development of PTP1B inhibitors requires integrated approaches that include allosteric modulation, tissue-specific delivery, and patient stratification to achieve successful clinical translation across multiple disease indications."

Journal • Cardiovascular • CNS Disorders • Diabetes • Metabolic Disorders • Oncology • Targeted Protein Degradation • Type 2 Diabetes Mellitus • PTPN1 • PTPN2

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Ionis Pharmaceuticals, Inc. | N=96 ➔ 0

Enrollment change • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Status of research on natural protein tyrosine phosphatase 1B inhibitors as potential antidiabetic agents: Update. (PubMed, Biomed Pharmacother) - "However, the few PTP1B inhibitors that entered the clinic (Ertiprotafib, ISIS-113715, Trodusquemine, and JTT-551) were discontinued due to side effects or low selectivity. Molecules with broad chemical diversity extracted from natural products have been reported to be potent PTP1B inhibitors with few side effects. This article summarizes the recent PTP1B inhibitors extracted from natural products, clarifying the current research progress, and providing new options for designing new and effective PTP1B inhibitors."

Journal • Review • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • IR • LEP • PTPN1